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Abstract
Mucin-type O-glycans on leukocytes acquire functions once they contain core 2 branches, which can be synthesized by core
2 L1,6-N-acetylglucosaminyltransferase (C2GnT). Recently, understanding the roles of mucin-type O-glycans has been
significantly advanced by generating transgenic mice overexpressing C2GnT or knockout mice defective in C2GnT. This
review article summarizes previous results implicating the roles of mucin-type O-glycans and the most recent studies to test
such a hypothesis. These results, taken together, demonstrate that mucin-type O-glycans either facilitate or attenuate cell
adhesion depending on the structures of non-reducing termini. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mucin-type O-glycans are attached to glycopro-
teins that are present in mucins. Mucins are secreted
by epithelial cells found on duct linings and appar-
ently protect the epithelial cell layers from harsh
environments that contain proteases and bacteria.
Mucin-type O-glycans are also present in glycopro-
teins present in the plasma membrane. In particular,
glycoproteins present in hematopoietic cells have
been extensively studied and among those glycopro-
teins, glycophorin and leukosialin represent those
discovered earlier [1,2]. In this review article, we fo-
cused on leukosialin, which is present in a wide vari-
ety of leukocytes. This decision was made since gly-
cosylation of leukosialin has been extensively studied
in relation to its roles in cell-cell interaction. Readers
are encouraged to read other review articles to be-
come familiar with other aspects of mucin-type gly-
coproteins [3^5].
2. Leukosialin
2.1. Isolation and molecular characterization
Leukosialin or CD43 was ¢rst isolated from rat
thymocytes using the W3/13 monoclonal antibody
[6]. When the W3/13 antigen was isolated, it was
apparent that this molecule contains a large amount
of mucin-type O-glycans, because of the signi¢cant
quantity of N-acetylgalactosamine, galactose and
sialic acid. The molecule is rich in serine, threonine,
and proline, and is thus regarded as a glycophorin-
like molecule or mucin-like molecule. Glycophorin, a
major sialoglycoprotein of mature erythrocytes, was
shown to have a similar composition [7]. However,
the glycophorin-like molecule has an apparent mo-
lecular mass of about 100 kDa. In contrast, the
monomer of glycophorin A has a molecular mass
of about 36 kDa (Fig. 1).
During studies on erythroid di¡erentiation, it was
discovered that immature erythroid cells contain a
decreased amount of glycophorin [8,9]. Those cells,
instead, express another major sialoglycoprotein,
which disappears during erythroid maturation [8^
11]. Our initial intention was to isolate this molecule
as a di¡erentiation antigen speci¢c to early erythroid
cells. When this molecule was isolated, however, it
became evident that it is present in various leukemic
cell lines and the name leukosialin was given [12]. In
parallel to these studies, it was reported that a sialo-
glycoprotein is apparently defective in patients with
the Wiskott-Aldrich syndrome and a monoclonal
antibody (L10) was obtained that reacts with this
glycoprotein before and after desialylation [13]. The
apparent molecular mass of this glycoprotein esti-
mated by SDS-polyacrylamide gel electrophoresis is
about 115 kDa before desialylation, while it in-
creased to about 140 kDa after desialylation (see
below). The isoelectric point of the molecule is close
to pH 4.1 for intact molecules whereas it is pH 5.0
after removal of sialic acid.
By examining the property of these molecules, it
became evident that leukosialin is probably identical
to the molecule recognized by L10 and is related to
Fig. 1. Schematic structure of glycophorin A. Leukosialin and glycophorin A contain approx. 80 and 15 O-linked oligosaccharides, re-
spectively, and are denoted by S, while one N-glycan is denoted by 8. The potential phosphorylation site in leukosialin is indicated
by a circled P. The size of each domain is shown in proportion to sizes. (Based on [2,84,85].)
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the W3/13 antigen. First, all of these molecules are
enriched in carbohydrates of the mucin type and in
serine and threonine. Second, all of these molecules
have a molecular mass of 110^135 kDa and migrate
slower on SDS-gel electrophoresis after removal of
sialic acid residues. This phenomenon happens be-
cause mucin-type glycoproteins contain densely dis-
tributed O-glycans which inhibit the binding of SDS
[14]. Since the charge contributed by SDS is propor-
tional to the size of a protein, the total charge con-
tributed from bound SDS allows proteins to move
against a matrix when the electric current is applied.
However, mucin-type glycoproteins derive a substan-
tial amount of negative charge from sialic acid resi-
dues because highly clustered oligosaccharides inhibit
the binding of SDS to these glycoproteins. When
sialic acid residues are removed, the negative charge
is decreased but no increase in binding of SDS oc-
curs. This is the reason why desialylated mucin-type
glycoproteins migrate slower than intact molecules.
Finally, sequential immunoprecipitation showed that
these glycoproteins were identical or highly related to
each other [12].
Because of these important characteristics, the de-
termination of the amino acid sequence by cDNA
cloning was carried out on both rat and human leu-
kosialins [15^17]. The results clearly indicate that
more than 40% of the extracellular domain of leuko-
sialin is composed of serine and threonine residues.
Based on the ratio of carbohydrate to protein, this
implies that more than one-third of the amino acid
residues in the extracellular domain is occupied by
mucin-type O-glycans. This notion is reinforced by
the fact that leukosialin appears to be a rod-like
structure when examined by rotary shadowing elec-
tron microscopy [18], suggesting that highly clustered
oligosaccharides make this molecule into an extended
form. In addition, human leukosialin contains one
N-glycan site, which is utilized [12]. The cytoplasmic
domain contains 123 amino acids and is relatively
large compared to that of glycophorin A, which con-
tains 36 amino acids [7]. The amino acid sequence of
the cytoplasmic segment of leukosialin is well con-
served among di¡erent species [15^17] and has po-
tential phosphorylation sites. The gene for human
leukosialin is located on chromosome 16 band
p11.2 [16]. This locus for the leukosialin gene is close
to the locus for the K-subunits of LFA-1, Mac-1 and
p150/95, members of the leukocyte adhesion mole-
cule family [19], suggesting some functional signi¢-
cance of leukosialin as an adhesion molecule.
Leukosialin is expressed in the majority of leuko-
cytes but is absent in mature B lymphocytes. Imma-
ture large pre-B lymphocytes express leukosialin and
the immunoglobulin heavy and light chain rearrange-
ment takes place at this stage. After transition to
small B lymphocytes, leukosialin synthesis is turned
o¡. Once B cells are activated to di¡erentiate into B
lymphoblasts, leukosialin is re-expressed [20]. More-
over, transgenic mice that continuously express leu-
kosialin in mature B cells produced increased num-
bers of B cells in the peripheral blood and those B
cells exhibited decreased susceptibility to apoptosis
[21]. These results clearly indicate that turning on
and turning o¡ of the leukosialin gene is critical
for proper maturation of B cells.
It was shown that the promoter activity of leuko-
sialin is mainly caused by SP1 binding to the unique
sequence GGGTGG in the promoter [22,23]. Re-
cently it was discovered that methylation of CpG
in the leukosialin gene takes place in those cells
that do not express leukosialin, suppressing its tran-
scription [24,25]. This was also true when various
human tissues were examined. These results indicate
that the leukosialin gene is constitutively active be-
cause SP1 is present in almost all cells. However, in
those cells which do not express leukosialin, DNA
methylation of the leukosialin gene takes place,
thus suppressing transcription [24,25]. The regulation
of expression of the leukosialin is characteristic in
that the suppression of constitutive expression by
methylation determines the tissue-speci¢c expression
of a gene.
2.2. Oligosaccharide structures attached to
leukosialin: cell type-speci¢c expression
Since the discovery of leukosialin, it has been
noted that leukosialin displays cell type-speci¢c gly-
cosylation. First, it was demonstrated that leukosia-
lins from di¡erent leukemic cell lines display di¡erent
molecular weights [12]. Di¡erent leukemic cell lines
were pulse-labeled with [35S]methionine and leukosia-
lin was immunoprecipitated by peptide-speci¢c anti-
bodies. Despite the fact that the mature leukosialin
molecules from di¡erent cell lines display di¡erent
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molecular weights, the nascent polypeptides with a
single high-mannose oligosaccharide, detected after
a short chase, display the identical molecular weight.
These results thus establish that the polypeptide por-
tion of leukosialin is the same in di¡erent cell types
[12]. The di¡erence was found to be due to the
di¡erence in structures of O-glycans [26]. The high
molecular weight form of leukosialin contains
mainly the branched hexasaccharide NeuAc(K2-3)-
Gal(L1-3)[NeuAc(K2-3)Gal(L1-4)GlcNAc(L1-6)]Gal-
NAc while the low molecular weight form contains
almost exclusively the tetrasaccharide NeuAc(K2-3)-
Gal(L1-3)[(NeuAc(K2-6)]GalNAc [26]. Second, this
di¡erence is well correlated to cell types. Leukosialin
from resting T lymphocytes and erythroid precursor
cells has an apparent molecular mass of 110 kDa
while leukosialin of apparent molecular mass of
135 kDa is expressed on neutrophils and platelets
[10,12,26]. These results thus indicate that core 2
L-1,6-N-acetylglucosaminyltransferase, which forms
GlcNAc(L1-6) branches in O-glycans, is expressed
in a cell type-speci¢c manner and is present in neu-
trophils and platelets (see Fig. 1).
Thirdly and most importantly, leukosialin is con-
verted from a 115 kDa form to a 135 kDa form
when lymphocytes in the peripheral blood are acti-
vated by IL-2 and anti-CD3 antibodies [27]. Similar
changes were observed with other mitogens such as
L-phytohemagglutinin. It was shown clearly that rest-
ing T lymphocytes contain the tetrasaccharides while
activated T lymphocytes contain a signi¢cantly in-
creased amount of the branched hexasaccharides
(Fig. 2). This change was found to be due to the
dramatic increase of core 2 L-1,6-N-acetylglucosami-
nyltransferase [27]. Since O-glycans are densely at-
tached to leukosialin (Fig. 1), this change in oligo-
saccharides likely in£uences the roles of leukosialin
as adhesion molecule. It is also possible that ligand
may bind or may not bind to leukosialin depending
on the structures of oligosaccharides (see also Section
3).
2.3. Change in O-glycans during thymocyte
development
In contrast to the above clear-cut oligosaccharide
pro¢le, human thymocytes contain a mixture of leu-
kosialins that di¡er in molecular masses from
115 kDa to 135 kDa [28]. It was also shown that
leukosialin of rat thymocytes can be bound to peanut
Fig. 2. Structure and biosynthesis of O-glycans attached to leukosialin. Leukosialin (CD43) on resting T cells carries tetrasaccharides
(115 kDa glycoform) and CD43 on activated T cells carries branched hexasaccharide, core 2 O-glycans (130 kDa glycoform). The ex-
pression of the core 2 O-glycan is directed by core 2 L-1,6-N-acetylglucosaminyltransferase, C2GnT, that forms a crucial core 2
branch, denoted by boxes followed by L1,4-galactosyltransferase IV [86]. CD43-130 kDa glycoform carrying the core 2 O-glycans is
dominantly expressed in resting T cells from Wiskott-Aldrich syndrome patients. (Based on [27,36,43,71,72,86].)
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agglutinin but only after sialidase treatment [29,30].
More importantly, the oligosaccharides of human
thymocyte leukosialin were found to contain a mix-
ture of the tetrasaccharides and the hexasaccharides
[28]. Among them, monosialylated pentasaccharides,
NeuAc(K2-3)[Gal(L1-3)(Gal(L1-4)GlcNAc(L1-6)]Gal-
NAc and Gal(L1-3)[(NeuNAc(K2-3)Gal(L1-4)Glc-
NAc(L1-6)]GalNAc are present. The latter is reactive
with peanut agglutinin, since it has a Gal(L1-3)Gal-
NAc backbone without sialylation. It was also dis-
covered that immature thymocytes in the cortical
layer are not fully sialylated whereas mature medul-
lary thymocytes are highly sialylated [30,31]. Thus
immature thymocytes are preferentially bound to
peanut agglutinin.
Studies have demonstrated that there is a dramatic
change in O-glycans during human thymocyte devel-
opment. This was ¢rst found by immunostaining us-
ing T305 monoclonal antibody. T305 monoclonal
antibody was obtained after immunization with a T
lymphocytic leukemia cell line and by selection for
reactivity with leukemia cells or lymphocytes from
patients with rheumatoid arthritis disease [32]. It
was discovered that this T305 antibody reacts with
a high molecular weight form of leukosialin which
contains the branched hexasaccharides [32^34].
When this monoclonal antibody was used to stain
thymocytes, immature cortical thymocytes were
strongly positive while relatively mature thymocytes
in thymus medulla were almost completely negative.
The staining of leukosialin is uniform throughout
di¡erent thymocytes [35]. Consistent results were ob-
tained when the abundance of mRNA for core 2 L-
1,6-N-acetylglucosaminyltransferase, C2GnT [36],
was measured by in situ hybridization. The mRNA
of C2GnT was detected in cortical thymocytes
whereas medullary thymocytes scarcely expressed
the mRNA [35]. In contrast, the mRNA for
Gal(L1-3)GalNAc:(K-2,3)sialyltransferase was more
abundant in medullary thymocytes than cortical thy-
mocytes, consistent with the fact that cortical thymo-
cytes are reactive with peanut agglutinin [31]. These
results indicate that maturation of cortical thymo-
cytes to medullary thymocytes is associated with
changes in O-glycans [35]. It has been shown that
thymocyte-thymus epithelial cell interaction is critical
for maturation of thymocytes [37] and that this in-
teraction can be e⁄ciently inhibited by T305 anti-
body [35]. It is thus possible that thymocyte-thymus
epithelial interaction needs to be taken over by other
mechanisms once thymocytes enter into medullary
thymus. Such a switch in the oligosaccharides may
play a role in thymocyte selection by apoptosis since
maturation of cortical thymocytes to medullary thy-
mocytes is associated with the death of the majority
of thymocytes through the apoptotic process. In fact,
galectin-1 was implicated in selectively removing thy-
mocytes, and O-glycans are likely involved in the
recognition by galectin-1 [38]. The continuous ex-
pression of the hexasaccharides probably has an ad-
verse e¡ect on this interaction.
3. Dual roles of O-glycans in cell adhesion
Several studies suggest that leukosialin plays some
role(s) in cell adhesion through its O-glycans. First it
was shown that the interaction between B and T
lymphocytes can be increased dramatically when leu-
kosialin is co-expressed with T cell receptor complex
[39]. The results also suggest that B lymphocytes ex-
press a ligand for leukosialin. Second, it was shown
that leukosialin interferes with the adhesion of lym-
phocytes. When leukosialin was expressed in HeLa
cells, the adhesion of T lymphocytes to HeLa cells
was reduced. This inhibitory activity of leukosialin
was abolished, however, when HeLa cells expressing
leukosialin were treated with sialidase [40]. Since T
lymphocytes bind to HeLa cells through LFA-1
binding to ICAM-1 on HeLa cells, these results in-
dicate that O-glycans on leukosialin might regulate T
cell adhesion by interfering with LFA-1 binding to
ICAM-1, a major activation-induced adhesion path-
way among lymphocytes. Similar ¢ndings were ob-
served in cell division. Leukosialin was found to be
concentrated in the cleavage furrow in both mitotic
phase and interphase. Such a highly restricted distri-
bution of leukosialin likely provides repulsion by
negative charges due to sialic acid, then facilitates
the dissociation of two dividing cells [41]. Third, a
soluble form of leukosialin is present in plasma [42].
The carbohydrate composition of this soluble leuko-
sialin is the same as that found on granulocytes [43]
and activated T lymphocytes [27]. This soluble form
is the result of proteolytic shedding from these cells
and this shedding of leukosialin from granulocytes is
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necessary for spreading and adhesion of activated
granulocytes [44]. Leukosialin is also shed when T
lymphocytes are activated [45]. These results strongly
suggest that leukosialin plays some roles in cell ad-
hesion of granulocytes and cell-cell interaction be-
tween T and B lymphocytes. In relation to this, it
is noteworthy that some of these roles are most likely
carried out by mucin-type O-glycans attached to leu-
kosialin (see Section 5).
It was shown that the sialyl Lex structure is present
both in O-glycans from granulocytes [43] and leuko-
sialin of HL-60 cells [46]. In these oligosaccharides,
we found that branches extended from the
GlcNAc(L1-6)GalNAc arm contain N-acetyllactos-
aminyl units. Moreover, when C2GnT was expressed
in Chinese hamster ovary cells, which lack endoge-
nous C2GnT, it was found that the cells not only
expressed the core 2 branch but also poly-N-acetyl-
lactosamine extension [34]. Thus it appears that the
formation of the core 2 branch by C2GnT is required
for sialyl Lex formation in many cells. In fact, it was
shown that activated T lymphocytes express the sial-
yl Lex structure while resting T lymphocytes do not
[47]. This structure is presumably present on poly-N-
acetyllactosaminyl O-glycans since only activated
cells synthesize these oligosaccharides. Sialyl Lex
structure is apparently formed only when E- and P-
selectin-mediated adhesion needs to occur. These se-
lectins appear at the surface of endothelial cells when
these cells are stimulated by in£ammatory agents.
Sialyl Lex is the ligand for E- and P-selectin; gran-
ulocytes and monocytes are recruited to in£amma-
tory sites by binding of their carbohydrates to these
selectins on activated endothelial cells [48^50]. These
results indicate that the formation of core 2 based
oligosaccharides leads to interaction of activated T
lymphocytes with endothelial cells at in£ammatory
sites. On the other hand, granulocytes constitutively
synthesize core 2-based oligosaccharides expressing
sialyl Lex structure [43,51] and can be bound to E-
and P-selectin on activated endothelial cells. More
recently, the gene for core 2 GnT was abrogated in
mice and the results obtained on those mice demon-
strate that core 2 branched O-glycans play a major
role in selectin ligand presentation on neutrophils
([52]; see also next section).
Although leukosialin contains sialyl Lex, it is not
clear whether or not leukosialin plays a dominant
role in presenting E- and P-selectin ligands. In fact,
expression cloning of P-selectin ligand resulted in
identifying another glycoprotein, P-selectin glycopro-
tein ligand-1 (PSGL-1) [53]. PSGL-1 contains a mu-
cin-type domain as does leukosialin. However, P-se-
lectin binds much better to PSGL-1 when a tyrosine
residue close to the NH2 terminus is sulfated and
sialyl Lex is present [51,54,55]. Because of this unique
property, PSGL-1 serves well as a P-selectin ligand
carrier. PSGL-1 is also a ligand for E-selectin [56,57],
while ESL-1, a variant of a receptor for ¢broblast
growth factor, was shown to be an E-selectin ligand
[58].
During in£ammation, it has been shown that E-
selectin-mediated adhesion of neutrophils leads to
stronger adhesion to endothelial cells through integ-
rins and counter-receptor interaction [59,60]. Once
such initial interaction is established, neutrophils
cross the boundary between endothelial cells, then
establish extravasation. It was demonstrated that
monocyte and neutrophil extravasation can be inhib-
ited by interference of the ¢rst step, the rolling e¡ect,
with anti-P- or anti-E-selectin antibody [60]. It was
also shown that E-selectin mediates acute lung in-
£ammation induced by deposition of IgG-immune
complexes and that such in£ammation can be inhib-
ited by administration of sialyl-Lex-glycopeptides or
oligosaccharides [61].
As described above, a soluble form of leukosialin
is produced from activated lymphocytes and granu-
locytes, which probably has a sialyl Lex terminal
structure. A soluble leukosialin isolated from CHO
cells, which were made to express sialyl Lex, was
found to be a potent inhibitor of E-selectin-mediated
cell adhesion [62]. These results strongly suggest that
a soluble leukosialin in the plasma may be a modu-
lator in selectin-mediated adhesion of granulocytes
and lymphocytes. Such a soluble leukosialin may
suppress the excessive reaction in the in£ammatory
process by binding to E- and P-selectins present on
activated endothelial cells.
Tumor cells could also utilize selectin-carbohy-
drate interaction when tumor cells adhere at meta-
static sites. In fact, tumor cells, in particular carcino-
ma and leukemic cells, have been shown to be
enriched with sialyl-Lex and sialyl-Lea structures
[63^66], which are ligands for E- and P-selectins
[48^50,67]. It has also been shown that some tumor
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cells aggregate with platelets [68] that presumably
express P-selectin. Such aggregated cells then could
be trapped in capillary tubes, which could then trig-
ger the activation of endothelial cells leading to the
expression of E-selectin. It is possible that these
events lead to the lodging of tumor cells in capillary
beds at junctions between endothelial cells [68].
It was shown that the expression of sialyl Lex and
sialyl Lea in core 2 branched O-glycans is highly
related to venous invasion and lymphatic invasion
of colonic carcinoma cells [69]. In earlier studies,
the expression of sialyl Lex is correlated with poor
prognosis of colonic tumor patients [65]. More re-
cently, it has been demonstrated that acquisition of
sialyl Lex on B16 melanoma cells, by transfection of
fucosyltransferase III, resulted in a dramatic increase
of lung tumor foci formation in mice [70]. These
results, as a whole, indicate that sialyl Lex and sialyl
Lea on tumor cells facilitate tumor formation by ad-
hesion to endothelial cells at metastatic sites, possibly
through their interaction with E- and P-selectin.
4. O-Glycans in immunode¢ciency
Since mucin-type glycoproteins are present as
dominant cell surface glycoproteins in hematopoietic
cells, the alteration of glycosylation of these glyco-
proteins apparently a¡ects immune responses. In
particular, extensive studies have been made on the
Wiskott-Aldrich syndrome and AIDS.
First, peripheral lymphocytes from patients with
the Wiskott-Aldrich syndrome have leukosialin that
has an increased molecular weight. When O-glycans
attached to leukosialin were analyzed, it was discov-
ered that those from patients have a signi¢cantly in-
creased amount of the hexasaccharides NeuAc(K2-3)-
Gal(L1-3)[(NeuAc(K2-3)Gal(L1-4)GlcNAc(L1-6)]Gal-
NAc. This increase of the hexasaccharides is due to
an increased amount of core 2 L-1,6-N-acetylglucos-
aminyltransferase, C2GnT, that forms a crucial L-
1,6-N-acetylglucosaminyl branch [71,72]. It is appar-
ent that T lymphocytes in the peripheral blood from
patients display an increased amount of C2GnT,
thus explaining the increased molecular weight of
leukosialin. Because of this anomaly, it is possible
that leukosialin was thought to be defective in earlier
studies [13].
As shown in Section 2, the expression of core
2-based oligosaccharides is characteristic to imma-
ture thymocytes. Moreover, lymphocytes from pa-
tients with leukemia and AIDS, another immunode-
¢cient syndrome, express a signi¢cant amount of
core 2-based hexasaccharides [28]. In fact, recent
studies demonstrated that the amount of core 2-
based hexasaccharides is highly correlated with the
progression of AIDS and is reversely correlated with
the increased number of CD4 cells during treatment
[73]. These results thus strongly suggest that the phe-
notype of the Wiskott-Aldrich syndrome may repre-
sent the characteristics of immature cells. In the thy-
mus of patients with this syndrome, it is likely that
immature, non-functional thymocytes (T lympho-
cytes) are released into the peripheral blood. This
may be the reason why T lymphocytes from patients
with this syndrome contain the hexasaccharides
present on immature thymocytes and are as non-
functional as immature thymocytes. Moreover, the
continuous drain of immature thymocytes may lead
to the depletion of T lymphocytes with age and con-
sequent depletion of T cell dependent regions of
lymph nodes and spleen.
It is noteworthy that AIDS patients have autoanti-
bodies against leukosialin, which appear to react
with leukosialin derived from neutrophils and acti-
vated T lymphocytes [74,75]. It is likely that these
antibodies react with immature thymocytes, remov-
ing T cell precursors. The presence of such antibodies
thus is probably one of the causes for immunode¢-
ciency in AIDS. Although there is no report on
whether autoantibodies are present or not in the
case of Wiskott-Aldrich syndrome, such a possibility
certainly exists, considering those patients which ex-
press core 2 branched O-glycans on their T cells for a
long period. If that is the case, those antibodies
surely contribute to the depletion of T lymphocyte
precursors from thymus.
It is also important to point out that the genetic
locus for leukosialin (chromosome 16, band p11.2)
[16] is entirely di¡erent from the genetic locus for
the defect in the Wiskott-Aldrich syndrome (X chro-
mosome, band p11-p11.3). It is still possible that the
gene a¡ected in the Wiskott-Aldrich syndrome is one
of the transcription factors for C2GnT. It is tempting
to speculate that the gene product defective in the
Wiskott-Aldrich syndrome [76] does not allow the
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turning o¡ of the C2GnT gene in the medulla. If
C2GnT is continuously activated during thymocyte
development, those thymocytes might fail to undergo
maturation in the medulla part of the thymus. If that
is the case, immature and dysfunctional thymocytes
circulate in the peripheral blood. Further studies,
thus, should be directed to understand how di¡er-
entiation of T lymphocytes is defective in the Wis-
kott-Aldrich syndrome in relation to the roles of O-
glycans.
5. Roles of O-glycans determined by transgenic or
gene knockout mice
Since C2GnT was cloned previously [36], it is now
possible to determine the roles of core 2 branched
oligosaccharides by either overexpressing C2GnT or
abolishing its expression.
Mouse C2GnT gene was thus cloned in a vector
that expresses the gene under the control of the lck
promoter. The lck promoter was shown to direct the
gene in a T cell-speci¢c manner and thus only T cells
showed an increased amount of C2GnT, which is
comparable to that expressed in T cells of patients
with the Wiskott-Aldrich syndrome [77]. T cells from
the transgenic mice display impaired immune re-
sponses. This was clearly demonstrated by delayed
hypersensitivity assay (Fig. 3) and cell proliferation
assay using anti-CD3 and ICAM-1. Since these im-
mune responses are dependent on the interaction be-
tween T cell and antigen-presenting cells, such inter-
action was thought to be impaired in these T cells
from the transgenic mice. In fact, T cells from the
transgenic mice adhered less e⁄ciently to ICAM-1
and ¢bronectin, which are present on antigen-pre-
senting cells (Fig. 4). Immune responses of B cells,
which are dependent on T cells, were also found to
be decreased in the transgenic mice. B cell prolifer-
ation responding to T cells derived from the trans-
genic mice was much less than that responding to T
cells derived from the control mice [78]. This re-
sponse was entirely dependent on the origin of T cells
and B cell response was identical regardless of
whether B cells were derived from the transgenic or
control mice. Similarly, immunoglobulin subclass
switching was delayed and germinal center formation
was impaired in the transgenic mice [78]. These re-
sults, as a whole, indicate that the interaction be-
tween T cells and antigen-presenting cells or between
T cells and B cells is signi¢cantly reduced when T
cells express bulky core 2 branched O-glycans. Such
a reduction in cell-cell interaction is most likely one
Fig. 4. Reduced adhesion of T cells from Lck-mC2GnT trans-
genic mice to ICAM-1 and ¢bronectin. Puri¢ed T cells from
normal and Lck-mC2GnT transgenic mice (see text) were la-
beled with [35S]methionine and tested for their ability to adhere
to mouse ICAM-1-IgG or murine ¢bronectin. The cells were in-
cubated with anti-mouse LFA-1 or anti-mouse E-selectin as an
isotype matched control before adding to the ligand coated
plates (from [77]).
Fig. 3. Lck-mC2GnT transgenic mice showed reduced delayed-
type hypersensitivity (DTH). Wild-type mice (control) and
transgenic mice overexpressing C2GnT (Lck-mC2GnT) were
sensitized with KLH. Seven days later, PBS and KLH were in-
jected into the right and left ears, respectively. Twenty-four
hours later, the thickness of ear swellings was measured. Each
symbol represents a di¡erent mouse (from [77]).
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of the causes for immunode¢ciency in the Wiskott-
Aldrich syndrome, AIDS and possibly leukemia. On
the other hand, the knockout of leukosialin gene
resulted in hyperimmune responses [79], since a large
proportion of O-glycans are absent on T cells of such
a mouse.
In relation to this, it is noteworthy that overex-
pression of sialo-mucin in other cells also resulted
in the decreased adhesion of cells [80]. Moreover,
such an increased expression of sialo-mucins resulted
in decreased attack by natural killer cells.
As a counterpart of the above studies, mouse
C2GnT gene was abrogated by homologous recom-
bination and the phenotype of the gene knockout
mice has been analyzed [52]. As a ¢rst of these sys-
temic studies, the functionality of selectin ligands was
examined. Under rolling conditions, neutrophils
lacking C2GnT showed very little binding to L-selec-
tin, while binding to P-selectin is moderately im-
paired. Interestingly, binding to E-selectin was
more impaired than binding to P-selectin. These re-
sults indicate that binding of neutrophils to L-, E-,
and P-selectins is in this order dependent on core 2
oligosaccharide structures.
Strikingly, mice lacking C2GnT exhibit almost no
impairment in lymphocyte homing [52]. The results
indicate that L-selectin ligand in high endothelial
venules (HEV) does not require core 2 branched oli-
gosaccharides or another separate C2GnT may exist
in HEV. However, the former possibility can be ex-
cluded since structural studies so far demonstrated
that all of L-selectin ligand structures contain core
2 branches [81]. In fact, the second possibility was
strengthened when a novel C2GnT was recently
cloned [82], and this newly cloned enzyme was shown
to catalyze core 2, core 4 and I branching activities,
in a ratio of 1.0:0.34:0.07 (or 0.03). Since this en-
zyme is exclusively present in those tissues synthesiz-
ing large amounts of mucin, such as stomach, small
and large intestines and trachea, it was termed
C2GnT-mucin type (C2GnT-M). On the other
hand, the previously cloned C2GnT [36] is widely
expressed in various tissues including leukocytes,
thus termed C2GnT-leukocyte type (C2GnT-L)
[82]. It is possible that C2GnT-M is present in high
endothelial venules and responsible for forming L-
selectin ligands.
6. Prospects
The studies on determining the roles of carbohy-
drates have been limited until recently and the results
obtained were mostly to reveal the correlation be-
tween the presence of a given structure and pheno-
type. Such e¡orts are, however, dramatically chang-
ing since many of the glycosyltransferases that form
speci¢c oligosaccharide structures are available now.
Continuous e¡orts to isolate more molecular tools
will allow us to manipulate the expression of a given
oligosaccharide providing acquired functions.
These studies have been exempli¢ed by one of the
pioneering studies in which the E-selectin ligand was
discovered to be sialyl Lex [83]. In this study, the
acquisition of sialyl Lex on Chinese hamster ovary
cells by transfecting fucosyltransferase III resulted in
their adhesion to E-selectin. More recently, the stud-
ies on C2GnT-L overexpression [77,78] or knockout
mice [58] also demonstrated excellent examples where
functionality of these oligosaccharides was tested. In
addition, gene knockout studies provided evidence
that core 2 branched oligosaccharides are the major
ligands for E-, P- and L-selectins on neutrophils.
At the same time, these studies revealed that an-
other related enzyme may exist for performing sim-
ilar or identical roles in certain tissues, such as the
high endothelial venules in this case. We cannot em-
phasize enough that these new research e¡orts need
to be vigorously pursued. Such research e¡orts will
unequivocally determine the roles of a given oligo-
saccharide by showing acquisition or loss of a par-
ticular function. Hopefully those e¡orts will extend
our strength in understanding the roles of carbohy-
drates in immune systems to other well de¢ned sys-
tems such as the nervous system.
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